TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20633254

Group type: EXPERIMENTAL
Intervention: Living alone and being a smoker or ex-smoker
Number of subjects: 651

Group type: COMPARATOR
Intervention: Socioeconomic status (social class, educational level, municipality family income)
Number of subjects: 651
Study: 18327363

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 15955470

Group type: EXPERIMENTAL
Intervention: Subtotal fasting (< 300 kcal/day, only from carbohydrates)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 12463616

Group type: EXPERIMENTAL
Intervention: Below-knee, Scholl, Flight Socks (14-17 mm Hg pressure at the ankle)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 657
Study: 10726353

Group type: EXPERIMENTAL
Intervention: Zoladex (GnRH agonist)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (without medication)
Number of subjects: 34
Study: 7562288

Group type: EXPERIMENTAL
Intervention: Amoxicillin prophylaxis (100 mg/kg per day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no prophylactic antibiotic treatment)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Amoxicillin prophylaxis
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 2265368

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg IV followed by infusion of 20 mg in 400 ml of 5% glucose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (400 ml of 5% glucose)
Number of subjects: 10
Study: 7005459

Group type: EXPERIMENTAL
Intervention: 4-day course of doxycycline therapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 10-day course of doxycycline therapy
Number of subjects: 105
Study: 30670270

Group type: EXPERIMENTAL
Intervention: Bikram yoga intervention (3-5 classes weekly for 16 weeks)
Number of subjects: 29
Study: 28105705

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat) with fluoride toothpaste
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Profluorid Varnish) with fluoride toothpaste
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fluoride varnish (Duraphat) without fluoride toothpaste
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fluoride varnish (Profluorid Varnish) without fluoride toothpaste
Number of subjects: 15
Study: 26306400

Group type: EXPERIMENTAL
Intervention: Hexanic Extract of Serenoa repens (HESr) 320mg
Number of subjects: 206

Group type: COMPARATOR
Intervention: Tamsulosin 0.4mg
Number of subjects: 206
Study: 23260452

Group type: EXPERIMENTAL
Intervention: Heterotopic noxious counter-stimulation (HNCS) with a flexible cold pack applied on the contralateral forearm.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suggestions of hyperalgesia.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suggestions of analgesia.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in shock-anxiety due to suggestions.
Number of subjects: 0
Study: 21681079

Group type: EXPERIMENTAL
Intervention: Aloe vera mouthwash
Number of subjects: 46

Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1%
Number of subjects: 46
Study: 18844015

Group type: EXPERIMENTAL
Intervention: NeoSoniX handpiece
Number of subjects: 659

Group type: COMPARATOR
Intervention: Standard handpiece
Number of subjects: 659
Study: 18690916

Group type: COMPARATOR
Intervention: Benzodiazepine hypnotics (recommended dose)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Benzodiazepine hypnotics (twice the recommended dose)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Zolpidem 20 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Zaleplon (10 and 20 mg)
Number of subjects: 207
Study: 14680731

Group type: EXPERIMENTAL
Intervention: Short-term enoxaparin 1 mg/kg subcutaneously twice a day
Number of subjects: 6098

Group type: EXPERIMENTAL
Intervention: Short-term unfractionated heparin (UFH)
Number of subjects: 6098

Group type: EXPERIMENTAL
Intervention: Continuation of a fixed-dose enoxaparin 60 mg subcutaneously twice a day
Number of subjects: 6098
Study: 11093970

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 82
Study: 9306168

Group type: EXPERIMENTAL
Intervention: Automated Auditory Brainstem Response (ABR)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Click Evoked Otoacoustic Emissions (EOAE)
Number of subjects: 200
Study: 8124120

Group type: EXPERIMENTAL
Intervention: Health checks by nurses (intervention group)
Number of subjects: 6124
Study: 2768695

Group type: EXPERIMENTAL
Intervention: 0.4% stannous fluoride (SnF2)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 0.22% sodium fluoride (NaF)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Fluoride-free placebo gel
Number of subjects: 281
Study: 336178

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cytoxan), regimen A
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide alternating with methotrexate, regimen B
Number of subjects: 417

Group type: COMPARATOR
Intervention: No additional therapy (control)
Number of subjects: 417
Study: 31689588

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS over SMA (N=20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS (N=10)
Number of subjects: 30
Study: 29275373

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 438

Group type: COMPARATOR
Intervention: No insulin
Number of subjects: 438

Group type: COMPARATOR
Intervention: No metformin
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 438
Study: 25975659

Group type: EXPERIMENTAL
Intervention: Uninterrupted rivaroxaban (20 mg once-daily)
Number of subjects: 248
Study: 24219882

Group type: EXPERIMENTAL
Intervention: Hormone therapy (transdermal estradiol 1 mg/d, oral estradiol 2 mg/d with or without medroxyprogesterone acetate 5 mg/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 23006063

Group type: EXPERIMENTAL
Intervention: Profiling group (dialysate temperature 35.5°C, variable sodium concentration [150-138 mEq/L], variable UF rate)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (dialysate temperature 37.0°C, fixed sodium concentration [138 mEq/L], fixed UF rate)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Profiling group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 19531961

Group type: EXPERIMENTAL
Intervention: Multifactorial continued educational and behavioral intervention for 2 years
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 52
Study: 17401691

Group type: EXPERIMENTAL
Intervention: Perceived access to recreational facilities
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Basketball courts within a mile of homes
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Total number of facilities perceived
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Number of facilities within a half-mile of girls' homes
Number of subjects: 1367

Group type: COMPARATOR
Intervention: Objective facility measures
Number of subjects: 1367
Study: 15249978

Group type: EXPERIMENTAL
Intervention: Medical test confirming blindness certificates
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Medical test grading
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Comparison of certificates and medical test results
Number of subjects: 117
Study: 11442161

Group type: EXPERIMENTAL
Intervention: SCP self-regulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication with new anticonvulsive drugs (AEDs) and psychosocial counseling (MED group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-control of respiratory parameters (RES group)
Number of subjects: 0
Study: 9169364

Group type: EXPERIMENTAL
Intervention: Aprotinin 1 million KIU
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 1531742

Group type: EXPERIMENTAL
Intervention: Morphine sulfate (group M, n = 54, up to 2 mg/kg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sufentanil (group S, n = 52, 1 microgram/kg and 1 microgram.kg-1.h-1)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sufentanil (group S)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Morphine sulfate (group M)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 3956454

Group type: EXPERIMENTAL
Intervention: Eterobarb
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eterobarb and Phenobarbital
Number of subjects: 0
Study: 30322793

Group type: EXPERIMENTAL
Intervention: Guided mindfulness-based meditation (GM)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Focused breathing (FB)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 76
Study: 29611221

Group type: EXPERIMENTAL
Intervention: Minimally rough implants (Turned surface - Tur)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moderately rough implants (TiUnite surface - TiU)
Number of subjects: 18
Study: 27438431

Group type: EXPERIMENTAL
Intervention: Allergy intervention (structured allergy history, skin prick testing, and appropriate allergy avoidance advice)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 335
Study: 24752682

Group type: EXPERIMENTAL
Intervention: Primaquine 0.5 mg/kg per day for 5 days (150 mg total)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Primaquine 0.5 mg/kg per day for 7 days (210 mg total)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Primaquine 0.25 mg/kg per day for 14 days (210 mg total)
Number of subjects: 540
Study: 21592596

Group type: EXPERIMENTAL
Intervention: Integrated Pain Management Program (IPMP)
Number of subjects: 147
Study: 19912315

Group type: EXPERIMENTAL
Intervention: Home orthostatic training (HOT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 38
Study: 17351280

Group type: EXPERIMENTAL
Intervention: Ephedrine HCl (25 mg, 3 times daily) plus caffeine (200 mg, 3 times daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ephedrine plus caffeine/pioglitazone (ECPio)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo/pioglitazone (PPio)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo/placebo (PP)
Number of subjects: 57
Study: 16324168

Group type: EXPERIMENTAL
Intervention: Noise (50 dB of white noise)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Negative affect (stressor challenge with difficult-to-solve anagrams and failure feedback)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (absence of both noise and negative affect)
Number of subjects: 68
Study: 11987055

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 64
Study: 9854329

Group type: EXPERIMENTAL
Intervention: Remifentanil combined with propofol (group 1: 100 micrograms/kg/min; n = 7)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Remifentanil combined with enflurane (group 2: 0.5 MAC; n = 8)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Remifentanil combined with isoflurane (group 3: 0.5 MAC; n = 8)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microgram/kg/min) during surgery
Number of subjects: 23
Study: 7608645

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dietary therapy (Control)
Number of subjects: 76
Study: 2405804

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 251

Group type: COMPARATOR
Intervention: Cholestyramine resin 4 to 12 g twice daily
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 251

Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 251
Study: 7357822

Group type: EXPERIMENTAL
Intervention: Elemental diet supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard low‐roughage diet
Number of subjects: 0
Study: 30920620

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/d) for 2 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d) for 2 weeks
Number of subjects: 22
Study: 28036410

Group type: EXPERIMENTAL
Intervention: 12 exposures of interactive book reading
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 24 exposures of interactive book reading
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 36 exposures of interactive book reading
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 48 exposures of interactive book reading
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Interactive book reading
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Children with poor phonological awareness, low vocabulary, and/or poor nonword repetition
Number of subjects: 27
Study: 25938213

Group type: EXPERIMENTAL
Intervention: 30-cm FOV
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 15-cm FOV
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10-cm FOV
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Human airway measurements
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Reduction from 30 to 15 cm
Number of subjects: 29
Study: 23360819

Group type: EXPERIMENTAL
Intervention: 8-week low-energy diet
Number of subjects: 0
Study: 20851843

Group type: EXPERIMENTAL
Intervention: IV Δ9‐tetrahydrocannabinol (THC) 2.5 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IV Δ9‐tetrahydrocannabinol (THC)
Number of subjects: 9
Study: 19820488

Group type: COMPARATOR
Intervention: Colclean and EasyCT (group 1)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Colclean and Tagitol V (group 2)
Number of subjects: 69

Group type: COMPARATOR
Intervention: LoSoPrep and EasyCT (group 3)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: LoSoPrep and Tagitol V (group 4)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Thick barium (Tagitol V)
Number of subjects: 69
Study: 17384438

Group type: EXPERIMENTAL
Intervention: Tolvaptan (30 mg/d)
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study: 15054171

Group type: EXPERIMENTAL
Intervention: HSV type specific serology testing
Number of subjects: 886

Group type: COMPARATOR
Intervention: Control group (sex matched clinic attendees)
Number of subjects: 886
Study: 11479396

Group type: EXPERIMENTAL
Intervention: alpha-dihydroergocryptine (DHEC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: L-Dopa alone
Number of subjects: 12
Study: 9692099

Group type: EXPERIMENTAL
Intervention: Budesonide 0.2 mg once daily
Number of subjects: 76

Group type: COMPARATOR
Intervention: Budesonide 0.1 mg twice daily
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Washout period
Number of subjects: 76
Study: 7921860

Group type: EXPERIMENTAL
Intervention: Autologous plasma transfusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: No autologous plasma transfusion
Number of subjects: 16
Study: 2898209

Group type: EXPERIMENTAL
Intervention: Dopexamine (0.25 to 4.0 micrograms/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline-placebo control
Number of subjects: 12
Study: 31959386

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.025 μg kg‐1 min‐1 (Group N1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.05 μg kg‐1 min‐1 (Group N2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.075 μg kg‐1 min‐1 (Group N3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.10 μg kg‐1 min‐1 (Group N4)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 80
Study: 30916005

Group type: EXPERIMENTAL
Intervention: Simulation education plus a didactic session on speaking up behaviour (SE+)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Simulation education (SE)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (SE and SE+)
Number of subjects: 22
Study: 28090679

Group type: EXPERIMENTAL
Intervention: Prucalopride (2 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25204974

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 23950861

Group type: EXPERIMENTAL
Intervention: Lung cancer warning (text only)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Addiction warning (text only)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Lung cancer warning (text plus image)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Addiction warning (text plus image)
Number of subjects: 386
Study: 20739419

Group type: COMPARATOR
Intervention: 1 g encapsulated soybean oil/d plus 14.7 g liquid soybean oil/d (control group)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 1 g encapsulated EPA/d plus 14.7 g liquid soybean oil/d (EPA group)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 1 g encapsulated soybean oil/d plus 14.7 g liquid SDA-enriched soybean oil/d (SDA group)
Number of subjects: 252
Study: 19202741

Group type: EXPERIMENTAL
Intervention: Test formulation (200 mg of faropenem)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation (200 mg of faropenem)
Number of subjects: 12
Study: 16901614

Group type: EXPERIMENTAL
Intervention: Monophasic cardioversion (MP) with cumulative energy (CE) >150J
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Monophasic cardioversion (MP) with cumulative energy (CE) <150J
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Biphasic cardioversion (BP) with cumulative energy (CE) >150J
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Biphasic cardioversion (BP) with cumulative energy (CE) <150J
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both groups (MP and BP)
Number of subjects: 141
Study: 12801490

Group type: EXPERIMENTAL
Intervention: Traditionally prepared homeopathic A. nitricum 12X
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Radionically-prepared A. nitricum 12X
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 10907676

Group type: EXPERIMENTAL
Intervention: Berocca
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 8654327

Group type: EXPERIMENTAL
Intervention: Method A (extensive quantitative food frequency questionnaire)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Method B (shorter quantitative food frequency questionnaire with a 14 day food record)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Combined food record with a quantitative food frequency questionnaire
Number of subjects: 206
Study: 1509971

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6402959

Group type: EXPERIMENTAL
Intervention: Cromolyn 40 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30832542

Group type: EXPERIMENTAL
Intervention: Telemedicine cochlear implant evaluation
Number of subjects: 13
Study: 29902464

Group type: EXPERIMENTAL
Intervention: Videos of black standardized patients (SPs)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Videos of white standardized patients (SPs)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Surgeon race (white versus other)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Patient race
Number of subjects: 113
Study: 26799064

Group type: EXPERIMENTAL
Intervention: PRIMAS (RCT)
Number of subjects: 254

Group type: COMPARATOR
Intervention: PRIMAS (Implementation Trial)
Number of subjects: 254
Study: 24634330

Group type: EXPERIMENTAL
Intervention: cHD with local citrate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: cHD with tinzaparin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: cHD using high-flux filter
Number of subjects: 23

Group type: COMPARATOR
Intervention: cHD using low-flux filter
Number of subjects: 23

Group type: COMPARATOR
Intervention: cHD patients
Number of subjects: 23
Study: 22582483

Group type: EXPERIMENTAL
Intervention: Intravenous intralipid 10% infusion (10 cc/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 30
Study: 19825502

Group type: EXPERIMENTAL
Intervention: Intensive computer-assisted cognitive rehabilitation of attention, information processing and executive functions for 3 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: No rehabilitation (Control Group)
Number of subjects: 150
Study: 17851140

Group type: EXPERIMENTAL
Intervention: 50mg sildenafil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16109827

Group type: EXPERIMENTAL
Intervention: Age (21-79 years)
Number of subjects: 58
Study: 12134253

Group type: EXPERIMENTAL
Intervention: Intrapartum nevirapine (200 mg to mother and 2 mg/kg to infant)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 10192340

Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (arm 1): 180 cGy per fraction, total dose 5400 cGy, plus 100 mg/m2 infusional cisplatin.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy (arm 2): 117 cGy per fraction, total dose 7020 cGy, plus 100 mg/m2 infusional cisplatin.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Both treatments (arm 1 and arm 2)
Number of subjects: 130
Study: 8584992

Group type: EXPERIMENTAL
Intervention: Warfarin (targeted International Normalized Ratio 2.0 to 3.0) for a further eight weeks
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Warfarin for a further eight weeks
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Three months of warfarin
Number of subjects: 301